<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre=": Original Paper Assessment of population susceptibility to upcoming seasonal" exact="influenza" post="epidemic strain using interepidemic emerging influenza virus strains Lin-Lei"/>
 <result pre="susceptibility to upcoming seasonal influenza epidemic strain using interepidemic emerging" exact="influenza" post="virus strains Lin-Lei Chen et al. Epidemiology and Infection"/>
 <result pre="any medium, provided the original work is properly cited.S0950268819001717a.pdf Seasonal" exact="influenza" post="virus epidemics have a major impact on healthcare systems."/>
 <result pre="impact on healthcare systems. Data on population susceptibility to emerging" exact="influenza" post="virus strains during the interepidemic period can guide planning"/>
 <result pre="period can guide planning for resource allocation of an upcoming" exact="influenza" post="season. This study sought to assess the population susceptibility"/>
 <result pre="study sought to assess the population susceptibility to representative emerging" exact="influenza" post="virus strains collected during the interepidemic period. The microneutralisation"/>
 <result pre="(MN titers) of a human serum panel against representative emerging" exact="influenza" post="strains collected during the interepidemic period before the 2018/2019"/>
 <result pre="strains collected during the interepidemic period before the 2018/2019 winter" exact="influenza" post="season (H1N1-inter and H3N2-inter) were compared with those against"/>
 <result pre="influenza season (H1N1-inter and H3N2-inter) were compared with those against" exact="influenza" post="strains representative of previous epidemics (H1N1-pre and H3N2-pre). A"/>
 <result pre="genetic and antigenic data, was used in selecting these representative" exact="influenza" post="virus strains for the MN assay. A significantly higher"/>
 <result pre="between H3N2-inter and H3N2-pre. Since A(H1N1) predominated the 2018–2019 winter" exact="influenza" post="epidemic, our results corroborated the epidemic subtype. Key words"/>
 <result pre="infections serology population susceptibility fig-count: table-count: ref-count: page-count: Introduction Seasonal" exact="influenza" post="virus infection has been associated with an estimated 9.4"/>
 <result pre="to 0.6 million deaths per year globally [1, 2]. During" exact="influenza" post="epidemics, the sudden surge in the number of patients"/>
 <result pre="$11.2 billion per year in the United States [5]. Seasonal" exact="influenza" post="epidemics are caused by influenza A(H1N1), A(H3N2) and influenza"/>
 <result pre="the United States [5]. Seasonal influenza epidemics are caused by" exact="influenza" post="A(H1N1), A(H3N2) and influenza B virus. There are important"/>
 <result pre="Seasonal influenza epidemics are caused by influenza A(H1N1), A(H3N2) and" exact="influenza" post="B virus. There are important epidemiological differences between these"/>
 <result pre="influenza B virus. There are important epidemiological differences between these" exact="influenza" post="viruses [6]. Studies have shown that the median ages"/>
 <result pre="Studies have shown that the median ages of patients with" exact="influenza" post="A(H1N1) (20 years) and influenza B (16 years) virus"/>
 <result pre="median ages of patients with influenza A(H1N1) (20 years) and" exact="influenza" post="B (16 years) virus infection are younger than those"/>
 <result pre="B (16 years) virus infection are younger than those with" exact="influenza" post="A(H3N2) (30 years) virus infection [7]. For influenza B"/>
 <result pre="those with influenza A(H3N2) (30 years) virus infection [7]. For" exact="influenza" post="B virus, patients infected by the Victoria lineage are"/>
 <result pre="born after 1947 [9]. Vaccine effectiveness is much lower for" exact="influenza" post="A(H3N2) virus than influenza A(H1N1) or influenza B virus"/>
 <result pre="Vaccine effectiveness is much lower for influenza A(H3N2) virus than" exact="influenza" post="A(H1N1) or influenza B virus [10]. These differences in"/>
 <result pre="much lower for influenza A(H3N2) virus than influenza A(H1N1) or" exact="influenza" post="B virus [10]. These differences in epidemiological characteristics and"/>
 <result pre="significant implication in healthcare resource and workforce planning for an" exact="influenza" post="season. An antibody titer against an influenza virus strain"/>
 <result pre="planning for an influenza season. An antibody titer against an" exact="influenza" post="virus strain correlates with protection against antigenically similar strains"/>
 <result pre="strain correlates with protection against antigenically similar strains [11]. As" exact="influenza" post="virus strains evolve, the population antibody titer against the"/>
 <result pre="will emerge as the predominant strain [12]. For example, the" exact="influenza" post="virus A(H1N1)pdm09 has quickly spread around the world because"/>
 <result pre="of this study is to determine the population susceptibility to" exact="influenza" post="viruses that are newly emerging in the interepidemic period."/>
 <result pre="as we described previously [12, 16]. We hypothesise that the" exact="influenza" post="subtype with a greater reduction in the antibody titer"/>
 <result pre="April to June 2018, which is after the 2017/2018 winter" exact="influenza" post="season. This study was approved by the HKU/HA HKW"/>
 <result pre="by the HKU/HA HKW Institutional Review Board (UW 18–141). Choosing" exact="influenza" post="A virus strains for microneutralisation assay Influenza A strains"/>
 <result pre="previous epidemics (H1N1-pre and H3N2-pre) and those representative of emerging" exact="influenza" post="strains collected during the interepidemic period before the 2018/2019"/>
 <result pre="strains collected during the interepidemic period before the 2018/2019 winter" exact="influenza" post="season (H1N1-inter and H3N2-inter) were chosen based on genetic"/>
 <result pre="(CI) as we described previously [23, 24]. Results Selection of" exact="influenza" post="A(H1N1) strains Before the 2018/2019 winter influenza season, the"/>
 <result pre="Results Selection of influenza A(H1N1) strains Before the 2018/2019 winter" exact="influenza" post="season, the last A(H1N1) epidemic occurred in the 2015/2016"/>
 <result pre="season, the last A(H1N1) epidemic occurred in the 2015/2016 winter" exact="influenza" post="season. S183P substitution in the HA, which was absent"/>
 <result pre="Influenza A strains emerging in Hong Kong. (a) Emergence of" exact="influenza" post="A(H1N1) strains with HA S183P substitution. (b) Emergence of"/>
 <result pre="influenza A(H1N1) strains with HA S183P substitution. (b) Emergence of" exact="influenza" post="A(H3N2) strains belonging to lineage 3C.2a1b. Amino acid sequences"/>
 <result pre="2018 and are indicated by the black arrows. Selection of" exact="influenza" post="A(H3N2) strains Phylogenetic analysis showed that A(H3N2) clade 3C.2a2"/>
 <result pre="2. Phylogenetic tree of HA showing the genetic relationship of" exact="influenza" post="A(H3N2) in Hong Kong. Nucleotide sequences were downloaded from"/>
 <result pre="Nucleotide sequences were downloaded from GISAID (Supplementary Table S2). All" exact="influenza" post="A(H3N2) strains from Hong Kong available at GISAID as"/>
 <result pre="for H3N2. Table 1. Comparison of microneutralisation antibody titer between" exact="influenza" post="A virus strains representative of previous epidemics and those"/>
 <result pre="than H3N2-pre. Table 2. Geometric mean microneutralisation antibody titer against" exact="influenza" post="A virus of each age group Geometric mean microneutralisation"/>
 <result pre="3). Table 3. Microneutralisation antibody titer of pooled serum against" exact="influenza" post="A H1N1 virus of each age group Microneutralisation antibody"/>
 <result pre="healthcare system. Assessing the population susceptibility to the upcoming epidemic" exact="influenza" post="strain is one of the important components in preparing"/>
 <result pre="strain is one of the important components in preparing for" exact="influenza" post="epidemics. In this study, we determined the population susceptibility"/>
 <result pre="the population susceptibility by comparing the antibody titers against representative" exact="influenza" post="virus strains that emerge during the interepidemic period with"/>
 <result pre="influenza virus strains that emerge during the interepidemic period with" exact="influenza" post="virus strains representative of those in the previous epidemic."/>
 <result pre="lower MN titers against H3N2-inter compared with H3N2-pre. For the" exact="influenza" post="season 2018/19 winter influenza season in Hong Kong, A(H1N1)"/>
 <result pre="H3N2-inter compared with H3N2-pre. For the influenza season 2018/19 winter" exact="influenza" post="season in Hong Kong, A(H1N1) was the predominant subtype"/>
 <result pre="[25]. Similarly, A(H1N1) subtype affects most hospitalised patients with laboratory-confirmed" exact="influenza" post="virus infection in the 2018/2019 season in Europe [26]."/>
 <result pre="season in Europe [26]. A(H1N1) is also the most predominant" exact="influenza" post="virus subtype affecting the United States [27]. Therefore, the"/>
 <result pre="States [27]. Therefore, the findings from our serosurveillance of interepidemic" exact="influenza" post="virus strains, which were collected before the 2018/2019 winter"/>
 <result pre="collected before the 2018/2019 winter epidemic, corroborated with the predominant" exact="influenza" post="virus subtype in the 2018/2019 winter epidemic. Although the"/>
 <result pre="virus subtype in the 2018/2019 winter epidemic. Although the predominant" exact="influenza" post="virus strains of a particular influenza subtype during an"/>
 <result pre="epidemic. Although the predominant influenza virus strains of a particular" exact="influenza" post="subtype during an influenza season can only be ascertained"/>
 <result pre="influenza virus strains of a particular influenza subtype during an" exact="influenza" post="season can only be ascertained after the influenza season"/>
 <result pre="during an influenza season can only be ascertained after the" exact="influenza" post="season has begun, these can be predicted by analysing"/>
 <result pre="season has begun, these can be predicted by analysing the" exact="influenza" post="virus strains collected during the interepidemic period. As seen"/>
 <result pre="found in most A(H1N1) strains collected in the 2018/19 winter" exact="influenza" post="season, showed a clear trend of increase since the"/>
 <result pre="season in 2015/16 winter. Our approach, which used representative emerging" exact="influenza" post="strains collected during the interepidemic period, provides population susceptibility"/>
 <result pre="a low-vaccine uptake rate. In Hong Kong, the overall seasonal" exact="influenza" post="uptake rate was only 14.8% as of 3 March"/>
 <result pre="assay instead of HA inhibition assay. Traditionally, antigenic characteristics of" exact="influenza" post="viruses are determined by haemagglutination inhibition assay (HAI) using"/>
 <result pre="30]. Other groups have developed models to predict the predominant" exact="influenza" post="virus subtype in the upcoming influenza season. These models"/>
 <result pre="to predict the predominant influenza virus subtype in the upcoming" exact="influenza" post="season. These models are based on the evolution rate,"/>
 <result pre="Europe, A(H3N2) was the predominant subtype in the 2018/2019 winter" exact="influenza" post="season. Second, we have used a limited number of"/>
 <result pre="influenza season. Second, we have used a limited number of" exact="influenza" post="virus strains. Third, one mutation arose during the virus"/>
 <result pre="virus, which was the virus subtype that predominated the 2018/2019" exact="influenza" post="season in Hong Kong. Our results support the use"/>
 <result pre="Public Health Laboratory Services of Hong Kong in providing the" exact="influenza" post="strain A/Hong Kong/656/2018; the division of Clinical Chemistry, Department"/>
 <result pre="2.collab: Collaborators GBDI (2019) Mortality, morbidity, and hospitalisations due to" exact="influenza" post="lower respiratory tract infections, 2017: an analysis for the"/>
 <result pre="Respiratory medicine7, 69–89.30553848 3.BeysardNet al. (2018) Impact of the 2014–2015" exact="influenza" post="season on the activity of an academic emergency department."/>
 <result pre="Kong. QJM112, 11–16.30295857 5.PutriWet al. (2018) Economic burden of seasonal" exact="influenza" post="in the United States. Vaccine36, 3960–3966.29801998 6.CainiSet al. (2018)"/>
 <result pre="Vaccine36, 3960–3966.29801998 6.CainiSet al. (2018) Clinical characteristics and severity of" exact="influenza" post="infections by virus type, subtype, and lineage: a systematic"/>
 <result pre="Viruses12, 780–792.29858537 7.BedfordTet al. (2015) Global circulation patterns of seasonal" exact="influenza" post="viruses vary with antigenic drift. Nature523, 217–220.26053121 8.SkowronskiDMet al."/>
 <result pre="antigenic drift. Nature523, 217–220.26053121 8.SkowronskiDMet al. (2017) Age-related differences in" exact="influenza" post="B infection by lineage in a community-based sentinel system,"/>
 <result pre="Infectious Diseases216, 697–702.28934439 9.BuddAPet al. (2019) Birth cohort effects in" exact="influenza" post="surveillance data: evidence that first influenza infection affects later"/>
 <result pre="Birth cohort effects in influenza surveillance data: evidence that first" exact="influenza" post="infection affects later influenza-associated illness. Journal of Infectious Diseases220,"/>
 <result pre="illness. Journal of Infectious Diseases220, 820–829.31053844 10.BelongiaEAet al. (2016) Variable" exact="influenza" post="vaccine effectiveness by subtype: a systematic review and meta-analysis"/>
 <result pre="studies. Lancet Infectious Diseases16, 942–951.27061888 11.MontoASet al. (2015) Antibody to" exact="influenza" post="virus neuraminidase: an independent correlate of protection. Journal of"/>
 <result pre="(2018) Low population serum microneutralization antibody titer against the predominating" exact="influenza" post="A(H3N2) N121K virus during the severe influenza summer peak"/>
 <result pre="against the predominating influenza A(H3N2) N121K virus during the severe" exact="influenza" post="summer peak of Hong Kong in 2017. Emerging Microbes"/>
 <result pre="presentation and outcome between adult patients suffering from the pandemic" exact="influenza" post="A (H1N1) 2009 virus and the seasonal influenza A"/>
 <result pre="the pandemic influenza A (H1N1) 2009 virus and the seasonal" exact="influenza" post="A virus infection. Postgraduate Medical Journal86, 515–521.20693151 14.ZhangAJet al."/>
 <result pre="Medical Journal86, 515–521.20693151 14.ZhangAJet al. (2011) High incidence of severe" exact="influenza" post="among individuals over 50 years of age. Clinical and"/>
 <result pre="Vaccine Immunology18, 1918–1924.21900532 15.ChengVCet al. (2012) Two years after pandemic" exact="influenza" post="A/2009/H1N1: what have we learned?Clinical Microbiology Reviews25, 223–263.22491771 16.ChanKHet"/>
 <result pre="Immunology18, 867–873.21411604 17.collab: World Health Organization (2018) Recommended composition of" exact="influenza" post="virus vaccines for use in the 2019 southern hemisphere"/>
 <result pre="influenza virus vaccines for use in the 2019 southern hemisphere" exact="influenza" post="season. Available athttps://www.who.int/influenza/vaccines/virus/recommendations/201809_recommendation.pdf (Accessed 20 December 2018). 18.ShuY and"/>
 <result pre="18.ShuY and McCauleyJ (2017) GISAID: Global initiative on sharing all" exact="influenza" post="data – from vision to reality. Eurosurveillance22, pii: 30494."/>
 <result pre="Influenza Surveillance Network. 21.LaurieKLet al. (2015) International laboratory comparison of" exact="influenza" post="microneutralization assays for A(H1N1)pdm09, A(H3N2), and A(H5N1) influenza viruses"/>
 <result pre="comparison of influenza microneutralization assays for A(H1N1)pdm09, A(H3N2), and A(H5N1)" exact="influenza" post="viruses by CONSISE. Clinical and Vaccine Immunology22, 957–964.26108286 22.WangYDet"/>
 <result pre="Journal30, 703–705. 23.HungIFet al. (2016) Topical imiquimod before intradermal trivalent" exact="influenza" post="vaccine for protection against heterologous non-vaccine and antigenically drifted"/>
 <result pre="al. (2012) High titer and avidity of nonneutralizing antibodies against" exact="influenza" post="vaccine antigen are associated with severe influenza. Clinical and"/>
 <result pre="1012–1018.22573737 25.collab: Centre for Health Protection (2019) Local situation of" exact="influenza" post="activity (as of Jan 9, 2019). Flu Express16, 1–9."/>
 <result pre="17 January 2019). 28.XieHet al. (2017) Differential effects of prior" exact="influenza" post="exposures on H3N2 cross-reactivity of human postvaccination sera. Clinical"/>
 <result pre="of the Hong Kong Special Administration Region (2019) LCQ11: Seasonal" exact="influenza" post="vaccination. Available athttps://www.info.gov.hk/gia/general/201903/20/P2019032000606.htm (Accessed 11 May 2019). 30.collab: European"/>
 <result pre="January 2019). 32.PetrovaVN and RussellCA (2018) The evolution of seasonal" exact="influenza" post="viruses. Nature Reviews Microbiology16, 60. 33.SkowronskiDMet al. (2016) A"/>
 <result pre="storm: impact of genomic variation and serial vaccination on low" exact="influenza" post="vaccine effectiveness during the 2014–2015 season. Clinical Infectious Diseases63,"/>
 <result pre="34.SmithDJet al. (2004) Mapping the antigenic and genetic evolution of" exact="influenza" post="virus. Science305, 371–376.15218094 35.DuXet al. (2017) Evolution-informed forecasting of"/>
 <result pre="virus. Science305, 371–376.15218094 35.DuXet al. (2017) Evolution-informed forecasting of seasonal" exact="influenza" post="A (H3N2). Science Translational Medicine9, pii: eaan5325.29070700 36.NeherRAet al."/>
 <result pre="(2016) Prediction, dynamics, and visualization of antigenic phenotypes of seasonal" exact="influenza" post="viruses. Proceedings of the National Academy of Sciences113, E1701–E1709."/>
 <result pre="Sciences113, E1701–E1709. 37.collab: World Health Organization (2019) Recommended composition of" exact="influenza" post="virus vaccines for use in the 2019–2020 northern hemisphere"/>
 <result pre="influenza virus vaccines for use in the 2019–2020 northern hemisphere" exact="influenza" post="season. Available athttps://www.who.int/influenza/vaccines/virus/recommendations/2019_20_north/en/ (Accessed 20 May 2019). 38.ZostSJet al."/>
 <result pre="athttps://www.who.int/influenza/vaccines/virus/recommendations/2019_20_north/en/ (Accessed 20 May 2019). 38.ZostSJet al. (2017) Contemporary H3N2" exact="influenza" post="viruses have a glycosylation site that alters binding of"/>
</results>
